Hedia Announces New CEO Rasmus Kofoed to Lead Diabetes Tech Company
On December 1, 2025, a significant leadership transition will take place at Hedia, a pioneering Danish technology firm specializing in diabetes management. Rasmus Kofoed has been appointed as the new Chief Executive Officer (CEO), succeeding Lars Christian Lund who has decided to resign after approximately two years in his role. Lund will assume the helm as the CEO of another international company. Under Lund's leadership, Hedia has seen remarkable growth and development, establishing itself as a prominent player in the digital diabetes management sector and therapeutic technology since its inception in 2016. Hedia is dedicated to creating digital solutions that enable insulin-dependent diabetics to better understand and manage their treatment through data, artificial intelligence, and user-friendly technology.
Carl Bilbo, the chairman of Hedia's board of directors, commended the previous CEO's contributions. He noted, "During Lars Christian Lund's tenure, Hedia has evolved into a flourishing company marked by robust regulatory and commercial development. His efforts were instrumental in reinforcing the organization, securing regulatory approvals, and laying the groundwork for global growth. We are grateful for his exceptional dedication and contributions."
The board welcomes Rasmus Kofoed, who brings a wealth of experience in the life sciences and medical technology sectors. His previous roles include senior positions at major companies like Novo Nordisk, Abbott, Roche, and Medtronic. Additionally, he served as the CEO of ChemoMetec, overseeing commercial and strategic global responsibilities, focusing on growth, transformation, and international expansion. Kofoed is well-poised to lead Hedia in its next phase of growth, aiming to further enhance its product offerings, market presence, and global partnerships.
In his statement, Rasmus Kofoed expressed enthusiasm about joining Hedia. "I see enormous potential in Hedia. The company combines clinical expertise and technology in a way that truly creates value for diabetics. I look forward to collaborating with the team to expand our reach and solidify our partnerships, ensuring Hedia emerges as a key player in digital diabetes care."
With this leadership change, Hedia sets out on an exciting new chapter in its growth journey, reaffirming its commitment to expanding its international footprint and enhancing its commercial engagements. Under the new leadership, Hedia aims to build upon its existing strengths while carving out new opportunities in the diabetes management space, thus aiming for a profound impact on patients' lives around the world. Hedia's commitment remains steadfast: to utilize advanced technology to elevate the standards of diabetes care, driving innovation and accessibility for all insulin-dependent individuals.
For more information about Hedia, visit their official website at www.hedia.com. Photos and additional materials related to this announcement can be found at the provided links.
Carl Bilbo, the chairman of Hedia's board of directors, commended the previous CEO's contributions. He noted, "During Lars Christian Lund's tenure, Hedia has evolved into a flourishing company marked by robust regulatory and commercial development. His efforts were instrumental in reinforcing the organization, securing regulatory approvals, and laying the groundwork for global growth. We are grateful for his exceptional dedication and contributions."
The board welcomes Rasmus Kofoed, who brings a wealth of experience in the life sciences and medical technology sectors. His previous roles include senior positions at major companies like Novo Nordisk, Abbott, Roche, and Medtronic. Additionally, he served as the CEO of ChemoMetec, overseeing commercial and strategic global responsibilities, focusing on growth, transformation, and international expansion. Kofoed is well-poised to lead Hedia in its next phase of growth, aiming to further enhance its product offerings, market presence, and global partnerships.
In his statement, Rasmus Kofoed expressed enthusiasm about joining Hedia. "I see enormous potential in Hedia. The company combines clinical expertise and technology in a way that truly creates value for diabetics. I look forward to collaborating with the team to expand our reach and solidify our partnerships, ensuring Hedia emerges as a key player in digital diabetes care."
With this leadership change, Hedia sets out on an exciting new chapter in its growth journey, reaffirming its commitment to expanding its international footprint and enhancing its commercial engagements. Under the new leadership, Hedia aims to build upon its existing strengths while carving out new opportunities in the diabetes management space, thus aiming for a profound impact on patients' lives around the world. Hedia's commitment remains steadfast: to utilize advanced technology to elevate the standards of diabetes care, driving innovation and accessibility for all insulin-dependent individuals.
For more information about Hedia, visit their official website at www.hedia.com. Photos and additional materials related to this announcement can be found at the provided links.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.